Best Practice & Research Clinical Rheumatology
Volume 22, Issue 1 , Pages 101-111 , March 2008

Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders

  • Stuart H. Ralston, MD, FRCP, F.Med.Sci, FRSE (ARC Professor of Rheumatology)

      Affiliations

    • Corresponding Author InformationTel.: +44 (0)131 6511037; Fax: +44 (0) 131 651 1085.

References 

  1. Kanis JA. Pathophysiology and treatment of Paget's disease of bone. 2nd edn. London: Martin Dunitz; 1998;pp. 1–303
  2. Sofaer JA, Holloway SM, Emery AE. A family study of Paget's disease of bone. Journal of Epidemiology and Community Health. 1983;37:226–231
  3. Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. Journal of Bone and Mineral Research. 1991;6:495–500
  4. Hocking L, Slee F, Cundy T, et al. Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. Bone. 2000;26:577–580
  5. Osterberg PH, Wallace RG, Adams DA, et al. Familial expansile osteolysis. A new dysplasia. The Journal of Bone and Joint Surgery. British Volume. 1988;70:255–260
  6. Whyte MP, Mills BG, Reinus WR, et al. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. Journal of Bone and Mineral Research. 2000;15:2330–2344
  7. Nakatsuka K, Nishizawa Y, Ralston SH. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. Journal of Bone and Mineral Research. 2003;18:1381–1385
  8. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. The New England Journal of Medicine. 2002;347:175–184
  9. Kovach MJ, Waggoner B, Leal SM, et al. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Molecular Genetics and Metabolism. 2001;74:458–475
  10. Wallace RG, Barr RJ, Osterberg PH, Mollan RA. Familial expansile osteolysis. Clinical Orthopaedics and Related Research. 1989;248:265–277
  11. Hughes AE, Shearman AM, Weber JL, et al. Genetic linkage of familial expansile osteolysis to chromosome 18q. Human Molecular Genetics. 1994;3:359–361
  12. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–179
  13. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes & Development. 1999;13:2412–2424
  14. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:1566–1571
  15. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315–323
  16. Hughes AE, Ralston SH, Marken J, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genetics. 2000;24:45–48
  17. Johnson-Pais TL, Singer FR, Bone HG, et al. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. Journal of Bone and Mineral Research. 2003;18:376–380
  18. Palenzuela L, Vives-Bauza C, Fernandez-Cadenas I, et al. Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. Journal of Medical Genetics. 2002;39:E67
  19. Whyte MP, Reinus WR, Podgornik MN, Mills BG. Familial expansile osteolysis (excessive RANK effect) in a 5-generation American kindred. Medicine. 2002;81:101–121
  20. Reddy SV, Singer FR, Mallette L, Roodman GD. Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease. Journal of Bone and Mineral Research. 1996;11:1602–1607
  21. Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. Journal of Bone and Mineral Research. 2002;17:26–29
  22. Albagha OME, Rojas J, van't Hof RJ, et al. A mouse model of early onset Paget's disease of bone caused by an insertion mutation affecting the RANK signal peptide. Calcified Tissue International. 2007;80:S34
  23. Golob DS, McAlister WH, Mills BG, et al. Juvenile Paget disease: life-long features of a mildly affected young woman. Journal of Bone and Mineral Research. 1996;11:132–142
  24. Janssens K, de Vernejoul MC, de Freitas F, et al. An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. Bone. 2005;36:542–548
  25. Cundy T, Hegde M, Naot D, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Human Molecular Genetics. 2002;11:2119–2127
  26. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–319
  27. Chong B, Hegde M, Fawkner M, et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. Journal of Bone and Mineral Research. 2003;18:2095–2104
  28. Wuyts W, Van Wesenbeeck L, Morales-Piga A, et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone. 2001;28:104–107
  29. Daroszewska A, Hocking LJ, McGuigan FEA, et al. Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. Journal of Bone and Mineral Research. 2004;19:1506–1511
  30. Beyens G, Daroszewska A, De Freitas F, et al. Identification of sex specific effects of TNFRSF11B polymorphisms on the risk of Paget's disease of bone. Calcified Tissue International. 2007;80:S42
  31. Greenberg PB, Doyle FH, Fisher MT, et al. Treatment of Paget's disease of bone with synthetic human calcitonin: biochemical and roentgenologic changes. The American Journal of Medicine. 1974;56:867–870
  32. Doyle FH, Woodhouse NJ, Glen AC, et al. Healing of the bones in juvenile Paget's disease treated by human calcitonin. The British Journal of Radiology. 1974;47:9–15
  33. Spindler A, Berman A, Mautalen C, et al. Chronic idiopathic hyperphosphatasia. Report of a case treated with pamidronate and a review of the literature. The Journal of Rheumatology. 1992;19:642–645
  34. Tau C, Mautalen C, Casco C, et al. Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy. Bone. 2004;35:210–216
  35. Cundy T, Wheadon L, King A. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. Journal of Bone and Mineral Research. 2004;19:703–711
  36. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. The New England Journal of Medicine. 2003;349:457–463
  37. Cundy T, Davidson J, Rutland MD, et al. Recombinant osteoprotegerin for juvenile Paget's disease. The New England Journal of Medicine. 2005;353:918–923
  38. Kimonis VE, Kovach MJ, Waggoner B, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genetics in Medicine. 2000;2:232–241
  39. Caughey JE, Wynne JF, Jefferson N. Dystrophia myotonica associated with familial Paget's disease (osteitis deformans) with sarcomata. The Journal of Bone and Joint Surgery. British Volume. 1957;39-B:316–325
  40. McBride TI. Paget's disease and muscular dystrophy. Report of an unusual association in one family. Scottish Medical Journal. 1966;11:238–243
  41. Tucker WS, Hubbard WH, Stryker TD, et al. A new familial disorder of combined lower motor neuron degeneration and skeletal disorganization. Transactions of the Association of American Physicians. 1982;95:126–134
  42. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics. 2004;36:377–381
  43. Wang Q, Song C, Li CC. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. Journal of Structural Biology. 2004;146:44–57
  44. Frohlich KU, Fries HW, Rudiger M, et al. Yeast cell cycle protein CDC48p shows full-length homology to the mammalian protein VCP and is a member of a protein family involved in secretion, peroxisome formation, and gene expression. The Journal of Cell Biology. 1991;114:443–453
  45. Hartmann-Petersen R, Wallace M, Hoffman K, et al. The Ubx2 and Ubx3 cofactors direct Cdc48 activity to proteolytic and nonproteolytic ubiquitin-dependent processes. Current Biology. 2004;14:824–828
  46. Yen HC, Gordon C, Chang EC. Schizosaccharomyces pombe Int6 and Ras homologs regulate cell division and mitotic fidelity via the proteasome. Cell. 2003;112:207–217
  47. Richly H, Rape M, Braun S, et al. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell. 2005;120:73–84
  48. Rape M, Hoppe T, Gorr I, et al. Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone. Cell. 2001;107:667–677
  49. Zhong X, Shen Y, Ballar P, et al. AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation. The Journal of Biological Chemistry. 2004;279:45676–45684
  50. Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Human Molecular Genetics. 2007;16:919–928
  51. Muller JM, Deinhardt K, Rosewell I, et al. Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. Biochemical and Biophysical Research Communications. 2007;354:459–465
  52. Weihl CC, Dalal S, Pestronk A, Hanson PI. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Human Molecular Genetics. 2006;15:189–199
  53. Lucas GJ, Mehta SG, Hocking LJ, et al. Evaluation of the role of valosin-containing protein in the pathogenesis of familial and sporadic Paget's disease of bone. Bone. 2006;38:280–285
  54. Selby PL, Davie MW, Ralston SH, Stone MD. Guidelines on the management of Paget's disease of bone. Bone. 2002;31:366–373

PII: S1521-6942(07)00128-3

doi: 10.1016/j.berh.2007.11.005

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 1 , Pages 101-111 , March 2008

Article Tools

* Image Usage & Resolution